1. Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics – results from single oral dose studies in healthy volunteers. (8th April 2013) Authors: Stoch, S. Aubrey; Zajic, Stefan; Stone, Julie A.; Miller, Deborah L.; van, Lucas; Lasseter, Kenneth C.; Pramanik, Barnali; Cilissen, Caroline; Liu, Qi; Liu, Lida; Scott, Boyd B.; Panebianco, Deborah; Ding, Yu; Gottesdiener, Keith; Wagner, John A. Journal: British journal of clinical pharmacology Issue: Volume 75:Number 5(2013:May) Page Start: 1240 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗